Literature DB >> 29580941

Increased epoxyeicosatrienoic acids may be part of a protective mechanism in human ulcerative colitis, with increased CYP2J2 and reduced soluble epoxide hydrolase expression.

Yi-Er Qiu1, Jun Qin1, Yang Luo1, Shao-Lan Qin1, Yi-Fei Mu1, Ran Cun1, Hou-Li Jiang2, Jian-Jun Chen1, Min-Hao Yu1, Ming Zhong3.   

Abstract

BACKGROUND: Previous preclinical evidence has suggested that the elevation of epoxyeicosatrienoic acids (EETs) derived from the cytochrome P450 (CYP) epoxygenases-dependent metabolism of arachidonic acid has important anti-inflammatory effects. However, the levels of EETs and their synthetic and metabolic enzymes in human ulcerative colitis has not been evaluated.
METHOD: To evaluate EETs and the expression of relevant CYP isoforms and the metabolizing enzyme, soluble epoxide hydrolase (sEH), tissue biopsies were collected from 16 pairs of ulcerative colitis patients' tissues and matched with adjacent non-inflamed tissues. EETs were extracted from tissue homogenates and analyzed by liquid chromatography coupled with tandem mass spectrometry.
RESULTS: The concentration of EETs was higher in ulcerative colitis tissues compared with matched adjacent non-inflamed tissues (1.91 ± 0.98 ng/mg vs. 0.96 ± 0.77 ng/mg, mean ± SD, P < 0.01). As shown by immunohistochemistry, sEH was present in the cytoplasm and intestinal mucosa and showed a decline in ulcerative colitis tissues compared with matched adjacent non-inflamed tissues. Western blot analyses showed reduced sEH expression in ulcerative colitis tissues compared with matched adjacent non-inflamed tissues, whereas CYP2J2 increased in ulcerative colitis tissues (P < 0.05). However, there was no statistically significant difference observed in CYP2C8 and CYP2C9 protein expression between them (P > 0.05).
CONCLUSION: Our data suggest that the increase in EET levels may be part of a protective mechanism in ulcerative colitis. Furthermore, the concentration of EETs could be a key factor for drug therapy for ulcerative colitis.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CYP2J2; Epoxyeicosatrienoic acids; Human ulcerative colitis; Soluble epoxide hydrolase

Mesh:

Substances:

Year:  2018        PMID: 29580941     DOI: 10.1016/j.prostaglandins.2018.03.004

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  2 in total

1.  Increased risk for cerebral ischemic stroke in diabetes: genetically polymorphic CYP mediated production of neuroprotective EETs and sulfonylurea metabolism in relation with KATP channels.

Authors:  Umit Yasar; Melih O Babaoglu
Journal:  Acta Pharmacol Sin       Date:  2018-09-25       Impact factor: 6.150

2.  Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease.

Authors:  William C Reisdorf; Qing Xie; Xin Zeng; Wensheng Xie; Neetu Rajpal; Bao Hoang; Mark E Burgert; Vinod Kumar; Mark R Hurle; Deepak K Rajpal; Sarah O'Donnell; Thomas T MacDonald; Anna Vossenkämper; Lin Wang; Mike Reilly; Bart J Votta; Yolanda Sanchez; Pankaj Agarwal
Journal:  PLoS One       Date:  2019-04-19       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.